Merck & Co., Inc.

Stocks

MRK

US58933Y1055

Real-time Estimate Cboe BZX Other stock markets 02:17:02 2026-07-13 pm EDT			5-day change	1st Jan Change
123.56 ^USD	+0.02%		-2.52%	+17.41%

01:48pm	Cosmos Health, Libytec Enter Distribution Deal for Diabetes Drug	MT
10:51am	BMO Capital Adjusts Price Target on Merck & Co to $142 From $135, Maintains Outperform Rating	MT

Transcript : Merck & Co., Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-04-2026 10

Published on 06/04/2026 at 12:35 pm EDT - Modified on 06/04/2026 at 02:35 pm EDT

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Akash Tewari (Analysts)

Good morning, everyone. My name is Akash Tewari. I head our pharma and biotech efforts here on the research side for Jefferies. Joining us is Merck, a company

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Merck & Co., Inc.

01:48pm	Cosmos Health, Libytec Enter Distribution Deal for Diabetes Drug	MT
10:51am	BMO Capital Adjusts Price Target on Merck & Co to $142 From $135, Maintains Outperform Rating	MT
07:07am	JPMorgan Adjusts Price Target on Merck to $140 From $135, Maintains Overweight Rating	MT
Jul. 10	Merck Receives Fda Approval for Keytruda and Keytruda Qlex Each with Padcev as Treatment Before and After Surgery for Adults with Muscle-Invasive Bladder Cancer	CI
Jul. 10	Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA	DJ
Jul. 10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT
Jul. 10	Merck's Keytruda Combination Wins Expanded FDA Approval for Muscle Invasive Bladder Cancer	MT
Jul. 10	Berenberg Adjusts Price Target on Merck to $127 From $125, Keeps Hold Rating	MT
Jul. 09	Avacta appoints "seasoned" new deputy chair	AN
Jul. 09	Informa hires former Reuters chief Tom Glocer as chair	AN
Jul. 08	Merck Likely to Post Inline Q2 Revenue, RBC Says	MT
Jul. 08	Morgan Stanley Lifts Price Target on Merck to $113 From $112, Keeps Equalweight Rating	MT
Jul. 08	Wells Fargo Adjusts Price Target on Merck to $150 From $145	MT
Jul. 07	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Jul. 06	HSBC Adjusts Price Target on Merck & Co to $150 From $135	MT